Immunotherapy such as anti-PDL1 therapy has been shown to have more effect in FGFR wild-type tumors in bladder cancer cell lines while less effects from immunotherapy were observed in FGFR4-overexpressed gastric cancer cells [144,145]. This evidence concerns the gene CD274 and urinary bladder cancer.